Please login to the form below

Not currently logged in
Email:
Password:

Blincyto

This page shows the latest Blincyto news and features for those working in and with pharma, biotech and healthcare.

So far so good for Amgen's much-anticipated KRAS inhibitor

So far so good for Amgen's much-anticipated KRAS inhibitor

Amgen will also present data on a clutch of bispecific T-cell engager (BiTE) antibodies at ASCO, as it tries to build a pipeline behind its approved bispecific Blincyto (blinatumomab) for

Latest news

More from news
Approximately 5 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Pharma deals in September 2015 Pharma deals in September 2015

    Amgen, has had success with in-house bispecifics already, such as acute lymphoblastic leukaemia (ALL) treatment, Blincyto; the in-developme nt acute myeloid leukaemia (AML) therapy AMG 330; and multiple myeloma

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

What are you doing, Dave?
Artificial Intelligence (AI) is invading all areas of healthcare. Is it our saviour or our nemesis?...
Fake News is Bad for your Health
Ill informed patients make poor health decisions...
Secrets of Pharma Advertising
If the goal of branding is to be different, why do so many Pharma brand ads look the same?...

Infographics